Molecular Insight Pharmaceuticals, Inc. Names New CEO
New Management Prepares company for Next Phase of Growth
Cambridge, MA, June 19, 2003 – Molecular Insight Pharmaceuticals, Inc. (formerly Biostream, Inc.) announced the appointment of David S. Barlow as its chairman and CEO. Mr. Barlow has served the company as chairman since March 2000 and will now assume the additional responsibility of chief executive officer. Molecular Insight is an emerging biopharmaceutical company focused on developing innovative imaging pharmaceuticals that will meaningfully enhance the visualization and management of disease.
"David’s extensive experience and distinguished track record of nearly twenty-five years in the pharmaceutical and biopharmaceutical industries will serve Molecular Insight extremely well as we continue to evolve as a leader in molecular imaging," said John Babich, Ph.D., the company’s co-founder, President and Chief Scientific Officer. "He has repeatedly proven his ability to lead and build high performance organizations which create significant value for all of its constituents."
"I’m pleased to expand my role in Molecular Insight at this very important and exciting time for the company," said Mr. Barlow. "Based on our talented team, robust and innovative pipeline, proprietary platform technologies and high potential lead compound just completing a multi-center Phase II trial, we are strongly positioned to become a science-based leader in the rapidly emerging and highly promising field of molecular imaging."
About Molecular Imaging
Molecular imaging uses radiopharmaceuticals and advanced scanning modalities to detect the earliest changes in the molecular biology of the cell. Specific changes in gene expression, protein expression, protein function and biochemistry provide important insights into the nature and status of disease. This information enables earlier and more accurate disease detection, therapeutic selection and monitoring. The emergence of molecular imaging has advanced medical practice from anatomical and functional assessment to defining disease at the molecular level.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight is a privately held, emerging biopharmaceutical company based in Cambridge, Massachusetts. The company is focused on leveraging its proprietary technology platforms to develop innovative imaging pharmaceuticals that improve the visualization and management of disease. Molecular Insight has established a strong pipeline of product candidates focused on the large and growing markets in cardiology, cancer and neurology. The company’s lead compound, Zemiva™, for the detection of ischemia, is nearing completion of a multi-center Phase II clinical trial.
Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554